Streetbeat News

Stock Prices

ROL

Spruce Point Capital Management has issued a short report on Rollins, Inc. (ROL), predicting a 30-40% long-term downside risk for the company. The report cites changing industry dynamics, increased pressures such as rising customer churn and acquisition costs, and consumer resistance to recent price increases. It also warns that nearly 40% of Rollins' annual revenue growth has come from its acquisition strategy, which is facing challenges due to new private equity money backing pest control acquisition platforms. The report also questions Rollins' recent claims of improving gross margins and highlights the company's increasing leverage to repurchase shares while the Rollins family is accelerating stock sales.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 1:08 pm

AWIN

MKUL

VCIG

VINO

In Wednesday's pre-market session, 11 industrial stocks showed significant movement. Gaucho Group Holdings (VINO), VCI Global (VCIG), Capstone Green Energy (CGRN), Laser Photonics (LASE), and FREYR Battery (FREY) saw gains, while Molekule Group (MKUL), AERWINS Technologies (AWIN), Intelligent Living (ILAG), Terran Orbital (LLAP), Multi Ways Holdings (MWG), and Trinity Industries (TRN) experienced losses.

Portfolio Pulse from Benzinga Insights

October 04, 2023 | 1:06 pm

DESP

GMBL

HELE

QSG

In Wednesday's pre-market session, several consumer discretionary stocks saw significant movement. Despegar.com (DESP), QuantaSing Group (QSG), Kaixin Auto Hldgs (KXIN), Latham Group (SWIM), Kaival Brands Innovations (KAVL), and Forza X1 (FRZA) all saw gains, while Dixie Gr (DXYN), Helen Of Troy (HELE), Connexa Sports Techs (CNXA), Elys Game Technology (ELYS), Grove Collaborative Hldgs (GROV), and Esports Entertainment (GMBL) experienced losses.

Portfolio Pulse from Benzinga Insights

October 04, 2023 | 1:06 pm

ADXN

BCLI

FEMY

FRLN

LAB

SNTI

SONX

SYBX

TKNO

VTAK

VVOS

In Wednesday's pre-market session, several healthcare stocks saw significant movement. Freeline Therapeutics, Vivos Therapeutics, Brainstorm Cell, Sonendo, Senti Biosciences, and Synlogic saw increases in their stock prices, while Kineta, Femasys, Alpha Teknova, Catheter Precision, Standard BioTools, and Addex Therapeutics experienced decreases.

Portfolio Pulse from Benzinga Insights

October 04, 2023 | 1:06 pm

AGIL

ATEN

AUUD

PXLW

In Wednesday's pre-market session, several information technology stocks saw significant movement. Pixelworks (PXLW), Auddia (AUUD), LiveVox Hldgs (LVOX), Airspan Networks Hldgs (MIMO), WaveDancer (WAVD), and SEALSQ (LAES) saw gains, while A10 Networks (ATEN), AgileThought (AGIL), Vislink Technologies (VISL), Actelis Networks (ASNS), Tempo Automation Holdings (TMPO), and GSE Systems (GVP) experienced losses.

Portfolio Pulse from Benzinga Insights

October 04, 2023 | 1:05 pm

INTC

MBLY

Intel Corp (NASDAQ:INTC) announced plans to spin off its Programmable Solutions Group business as a standalone entity, aiming for accelerated growth and increased competitiveness. The standalone operations are expected to start on Jan.1, 2024. Intel's executive vice president, Sandra Rivera, will become the CEO of the new business. Intel's shares are trading higher following the announcement.

Portfolio Pulse from Adam Eckert

October 04, 2023 | 1:04 pm

Kineta has announced a $3 million registered direct offering priced at-the-market under Nasdaq rules, causing its shares to trade lower.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 1:03 pm

VVOS

Vivos Therapeutics has entered into strategic agreements with Ormco and On Demand Orthodontist to supply Spark Clear Aligners to its national network of providers. This has led to an increase in Vivos' share price.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 1:01 pm

UPWK

Upwork (NASDAQ:UPWK) has received various analyst ratings in the last quarter, with 1 bullish, 2 somewhat bullish, and 2 indifferent. The average price target is $14.8, indicating an upside from the current price of $11.45. This average has increased by 25.96% from the previous average price target of $11.75.

Portfolio Pulse from Benzinga Insights

October 04, 2023 | 1:00 pm

URGN

In the last quarter, UroGen Pharma (NASDAQ:URGN) received 3 bullish ratings and 1 indifferent rating from analysts. The company's average 12-month price target has increased by 164.71% from $17.00 to $45.00.

Portfolio Pulse from Benzinga Insights

October 04, 2023 | 1:00 pm